Ten patients with hepatoma who had received radiotherapy for their metastatic sites have been reviewed. In 13 lesions of bone metastasis in 7 patients complete pain relief from 5 lesions (38%) was achieved, while partial relief (54%) was obtained in other lesions. Of 3 patients with a brain metastasis, one attained complete symptomatic improvement with a 65% tumor reduction, and one of the remaining two gained a symptomatic palliation. In a patient with two pulmonary metastases, intraarterial chemotherapy showed a more remarkable effect when treatment was combined with radiotherapy than intraarterial chemotherapy alone. It may be concluded that radiation therapy is effected modality for palliating metastatic lesions of hepatoma.
Download full-text PDF |
Source |
---|
J Exp Clin Cancer Res
January 2025
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Recent advances in oncology research have highlighted the promising synergy between low-dose radiation therapy (LDRT) and immunotherapies, with growing evidence highlighting the unique benefits of the combination. LDRT has emerged as a potent tool for stimulating the immune system, triggering systemic antitumor effects by remodeling the tumor microenvironment. Notably, LDRT demonstrates remarkable efficacy even in challenging metastatic sites such as the liver (uveal) and brain (cutaneous), particularly in advanced melanoma stages.
View Article and Find Full Text PDFBMC Med Educ
January 2025
Division of General Internal Medicine, Department of Medicine, The Ottawa Hospital, Ottawa, Canada.
Introduction: Hospital strain has been shown to negatively impact physician wellness, educational experience, and patient care. To address rising service demands, a non-academic hospitalist service was implemented to reduce daily clinical teaching unit (CTU) census by approximately 30%. Secondary aims were to evaluate physician and trainee wellness on CTU as well as assess unintended adverse patient outcomes.
View Article and Find Full Text PDFSci Rep
January 2025
Center for Informatics Science (CIS), School of Information Technology and Computer Science, Nile University, 26th of July Corridor, Sheikh Zayed City, Giza, 12588, Egypt.
Breast cancer, with its high incidence and mortality globally, necessitates early prediction of local and distant recurrence to improve treatment outcomes. This study develops and validates predictive models for breast cancer recurrence and metastasis using Recurrence-Free Survival Analysis and machine learning techniques. We merged datasets from the Molecular Taxonomy of Breast Cancer International Consortium, Memorial Sloan Kettering Cancer Center, Duke University, and the SEER program, creating a comprehensive dataset of 272, 252 rows and 23 columns.
View Article and Find Full Text PDFClin Breast Cancer
January 2025
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA; Harvard Medical School, Boston, MA.
Background: We sought to evaluate prognostic factors in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and their relationship with short- and long-term overall survival (OS).
Methods: Using the Surveillance, Epidemiology, and End Results (SEER) database, we evaluated patients with de novo HER2-positive MBC diagnosed from 2010 to 2018. Univariate analyses were performed to determine effect of each variable on OS.
BMJ Open
January 2025
Department of Obstetrics and Gynecology, University of Toronto, Toronto, Ontario, Canada.
Objectives: To study the effect of implementing a Trial of Labour After Caesarean (TOLAC) delivery bundle with respect to decreasing caesarean delivery rates across five hospitals.
Design: Prospective quality improvement study.
Setting: Five Canadian hospital sites participated, two academic centres and three community hospitals, with annual delivery rates ranging from 2500 to 7500 per site.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!